• Главная
  • NEW DAY MEDICINE
  • 2 (88) 2026
  • 185 -2 (88) 2026 - Akhmedov Sh.J., Yuldasheva D.Kh. - RISK FACTORS AND MOLECULAR GENETIC MARKERS OF OSTEOPOROSIS DEVELOPMENT IN MIDDLE-AGED AND ELDERLY PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

185 -2 (88) 2026 - Akhmedov Sh.J., Yuldasheva D.Kh. - RISK FACTORS AND MOLECULAR GENETIC MARKERS OF OSTEOPOROSIS DEVELOPMENT IN MIDDLE-AGED AND ELDERLY PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

RISK FACTORS AND MOLECULAR GENETIC MARKERS OF OSTEOPOROSIS DEVELOPMENT IN MIDDLE-AGED AND ELDERLY PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE

Akhmedov Sh.J. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Yuldasheva D.Kh. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This study scientifically substantiates the key risk factors for the development of osteoporosis in 180 middle-aged and elderly patients of the main group with non-alcoholic fatty liver disease, as well as the distribution of genotypes and alleles of molecular genetic markers reflecting the liver–bone axis. In elderly patients, the AA genotype was identified in 25% of cases, which was significantly higher compared to the control group (5%). The obtained results indicate that this genotype represents an important age-associated risk factor that increases susceptibility to disease progression and related complications, particularly osteoporosis.

Keywords: non-alcoholic fatty liver disease, osteoporosis, genotype, allele, molecular genetic markers.

First page

1008

Last page

1014

For citation:Akhmedov Sh.J., Yuldasheva D.Kh. - RISK FACTORS AND MOLECULAR GENETIC MARKERS OF OSTEOPOROSIS DEVELOPMENT IN MIDDLE-AGED AND ELDERLY PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE//New Day in Medicine 2(88)2026 1008-1014 https://newdayworldmedicine.com/en/new_day_medicine/2-88-2026

List of References

  1. Абдураҳмонов АР, Рўзиқов НА, Махмудов МА. Ноалкогол ёғли жигар касаллиги (НАЖБП) ва метаболик синдром. Tibbiyot axborotnomasi. 2020;4(2):12–18.
  2. Каримова ГИ, Ҳамидов ФА. Остеопороз: ташхис ва профилактика. O‘zbekiston tibbiyot akademiyasi ilmiy ishlanmalari. 2019;3(1):45–52.
  3. Рахимова МА, Қодиров ДМ. DEXA усули билан остеопороз диагностикаси: клиник кўрсаткичлар. Zamonaviy tibbiyot. 2022;1(4):67–73.
  4. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. 5. DOI: 10.1002/hep.29367
  5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. DOI: 10.1016/j.jhep.2015.11.004
  6. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int. 2013;24(1):23–57. DOI: 10.1007/s00198-012-2074-y

    file

    download